Skip to Content
Uncategorized

Nuts to That

Severe, even life-threatening peanut allergies afflict 3 million people in the United States alone. The only protection now available is to avoid peanuts and their derivatives. While it’s easy to eschew peanut butter sandwiches, who’s to know if the chips at the office party were fried in peanut oil? Houston-based Tanox has begun human testing of a once-a-month injection to protect the peanut-averse from accidental exposure. The drug, Hu-901, is an antibody that blocks the immune reaction responsible for swelling and itching. People taking it probably won’t be able to eat nuts daily, but they should have more time to get help if they do eat those chips.

If Hu-901 is effective in preventing peanut allergies, Tanox may investigate its use against other food allergies. The company hopes a similar antibody to treat seasonal allergies and asthma will get regulatory approval by mid-2001.

Keep Reading

Most Popular

Large language models can do jaw-dropping things. But nobody knows exactly why.

And that's a problem. Figuring it out is one of the biggest scientific puzzles of our time and a crucial step towards controlling more powerful future models.

How scientists traced a mysterious covid case back to six toilets

When wastewater surveillance turns into a hunt for a single infected individual, the ethics get tricky.

The problem with plug-in hybrids? Their drivers.

Plug-in hybrids are often sold as a transition to EVs, but new data from Europe shows we’re still underestimating the emissions they produce.

Google DeepMind’s new generative model makes Super Mario–like games from scratch

Genie learns how to control games by watching hours and hours of video. It could help train next-gen robots too.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.